Clinical Trials Logo

Filter by:
NCT ID: NCT06344351 Recruiting - Clinical trials for Advanced Malignant Neoplasm

A Clinical Trial of TQB3006 Tablets in Patients With Advanced Malignant Cancer

Start date: April 25, 2024
Phase: Phase 1
Study type: Interventional

This study includes two stage: dose escalation and dose extension, with a single dose and a multiple dose study. This is a single-center, open, non-randomized, single arm, study to evaluate the safety, tolerability and pharmacokinetics of TQB3006 tables in patients with advanced malignant cancer.

NCT ID: NCT06344338 Recruiting - Clinical trials for Refractory Status Epilepticus

Application of tDCS Stimulation in Controlling Refractory Status Epilepticus

tDCS
Start date: March 31, 2024
Phase: N/A
Study type: Interventional

The purpose of the study is to assess the efficacy and safety of targeting tDCS stimulation for treatment of Refractory status epilepticus

NCT ID: NCT06344325 Not yet recruiting - Elective Surgery Clinical Trials

ED90 of Fospropofol Disodium in Induction and Maintenance of Anesthesia

Start date: May 1, 2024
Phase: Phase 4
Study type: Interventional

Exploring the 90% effective dose (ED90) of fospropofol disodium in induction and maintenance of anesthesia in adults of different ages, providing more clinical evidence for the application of fospropofol disodium in clinical anesthesia

NCT ID: NCT06344312 Active, not recruiting - Clinical trials for Stroke, Acute Ischemic

Effectiveness of Yangxue Qingnao Granules in Preventing Post Thrombolytic Hemorrhage Transformation in Patients With Acute Cerebral Infarction

Start date: January 1, 2024
Phase: N/A
Study type: Interventional

Evaluate the effectiveness of Yangxue Qingnao Granules in preventing post thrombolytic hemorrhage transformation in patients with acute cerebral infarction, and explore its possible mechanism

NCT ID: NCT06344299 Completed - Clinical trials for Pancreatic Ductal Adenocarcinoma

Predictors for Low Rates of Surgical Resection in Elderly Patients With Resectable Pancreatic Ductal Adenocarcinoma

Start date: January 1, 2023
Phase:
Study type: Observational

More and more older adults are diagnosed with pancreatic ductal adenocarcinoma (PDAC), but the rate of surgical resection in patients with resectable tumour is still low. Clinical workers need to take more attention to oncologic care in this group. It's significant to explore potential predictors for impacting elderly patients chose to abandon surgical resection.

NCT ID: NCT06344247 Recruiting - Obesity Clinical Trials

Comparison of the Efficacy and Safety of SGLT2i and GLP-1 Receptor Agonists in Obese Patients With Kidney Disease

Start date: September 1, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to exploring the changes in 24-hour urinary protein and renal function in obese patients with kidney disease after the application of sodium glucose cotransporter 2 inhibitors (SGLT2i) and glucagon like peptide-1 receptor agonists (GLP-1RA). Eligible patients were randomly and non-blindly allocated to four groups in a 1:1:1:1 ratio.The first group is the optimized treatment group, and patients in this group maintain the maximum dose/maximum tolerated dose of RAS blocker therapy. The second group is the optimized treatment + SGLT2i group. Participants in this group are titrated to the target dose (10 mg qd) in combination with dapagliflozin on the basis of optimized treatment. The third group is the optimized treatment + GLP-1RA group. Participants in this group will be titrated to the target dose (1mg qw) in combination with semaglutide on the basis of optimized treatment. The last group is the optimized treatment + SGLT2i + GLP-1RA treatment group, that is, based on the optimized treatment, combined with dapagliflozin titrated to the target dose (10 mg qd) and semaglutide titrated to the target dose (1 mg qw).

NCT ID: NCT06344156 Recruiting - Pancreatic Cancer Clinical Trials

Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy as an Adjuvant Therapy for Pancreatic Cancer

Start date: April 1, 2024
Phase: Phase 1
Study type: Interventional

The aim of this single center, single arm and prospective study is to explore the safety and efficacy of Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy in postoperative adjuvant treatment of Pancreatic Cancer

NCT ID: NCT06344104 Recruiting - Clinical trials for Resistant Hypertension

A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Asian Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension

BaxAsia
Start date: April 8, 2024
Phase: Phase 3
Study type: Interventional

The purpose of this study is to measure the efficacy and safety of baxdrostat in Asian participants with uHTN or rHTN. The main objective is to compare the difference in SBP change from baseline at Week 12 of treatment between participants receiving 2 mg baxdrostat or 1 mg baxdrostat tablets and participants receiving placebo tablets.

NCT ID: NCT06344091 Not yet recruiting - Clinical trials for Local Analgesia Via Infiltration

A Study of Bupivacaine Liposome Injection in Local Analgesia of Pediatric Patients

Start date: April 6, 2024
Phase: Phase 4
Study type: Interventional

The study is being conducted to evaluate the safety and efficacy of bupivacaine liposome injection for local infiltration analgesia in pediatric orthopedic surgery in the real world.

NCT ID: NCT06344065 Recruiting - Healthy Volunteers Clinical Trials

Immunogenicity and Safety of Diphtheria, Tetanus, Pertussis (DTaP) Vaccine in 3-month-old Infants

Start date: December 21, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety and immunogenicity of the DTaP in 3-month-old infants.